4-[6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl]-N-(2-pyrrolidin-1-ylethyl)benzamide | 1330075-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl]-N-(2-pyrrolidin-1-ylethyl)benzamide
• CAS: 1330075-35-8
• 化学式: C₂₃H₂₈N₆O
• 分子量: 404.515
• InChiKey: JSYLKZMQVLWOPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  Methyl 4-[6-[cyclopropylmethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]imidazo[1,2-b]pyridazin-3-yl]benzoate 在 盐酸 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 生成 4-[6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl]-N-(2-pyrrolidin-1-ylethyl)benzamide
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

  摘要：

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.115

文献信息

• Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models
  作者：Hiroki Shimizu、Tomonori Yamasaki、Yoshiyuki Yoneda、Fumihito Muro、Tomoaki Hamada、Takanori Yasukochi、Shinji Tanaka、Tadashi Toki、Mika Yokoyama、Kaoru Morishita、Shin Iimura

  DOI：10.1016/j.bmcl.2011.05.115

  日期：2011.8

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.